The global tyrosine kinase inhibitor market is expected to rise at a considerable CAGR during the forecast period (2022-2028). The prominent factors such as rise in incidences of various cancers other chronic diseases globally, development in healthcare facilities, and high adoption of digital healthcare technology are driving the growth of the global tyrosine kinase inhibitor market. Apart from these, the companies operating in the tyrosine kinase inhibitors industry are focusing on increasing their geographic presence by means of strategic acquisitions and collaborations with leading players & increasing FDA approvals of therapeutic drugs in their respective domains and geographies along with strong investment in R&D activities.
Browse the full report description of “Global Tyrosine Kinase Inhibitor Market Size, Share and Trends Analysis Report by Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others), by Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/tyrosine-kinase-inhibitor-market
For instance, in June 2021, AstraZeneca and HUTCHMED’s Orpathys had been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. The approval made Orpathys the only targeted medicine approved for these biomarker-selected patients in China. In addition, it was another novel medicine addition to company’s existing lung cancer portfolio.
Moreover, in October 2021, Novartis announced that the US FDA approved its Scemblix® (asciminib) for the treatment of chronic myeloid leukemia (CML) in two distinct indications. In addition, Novartis had initiated regulatory filings for Scemblix in multiple countries and regions across the globe. Further, in October 2021, Roche announced that the US FDA cobas® EGFR Mutation Test v2 as a companion diagnostic (CDx) for a broader group of therapies in the treatment of non-small cell lung cancer (NSCLC). The new and innovative approach by the FDA paved the way for future EGFR TKI therapies to utilise the cobas EGFR Mutation Test v2 to help identify patients for personalised medicine. Considering such approvals, considerable growth can be expected during the forecast period.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
• By Type
• By Application
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
Competitive Landscape- including Novartis International AG, AstraZeneca plc, Pfizer Inc., Bayer AG, F. Hoffmann-La Roche AG, and others.
Key questions addressed by the report
• What is the market growth rate?
• That segment and region dominate the market in the base year?
• That segment and region will project the fastest growth in the market?
• How does COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Tyrosine Kinase Inhibitor Market Report by Segment
By Type
By Application
Global Tyrosine Kinase Inhibitor Market Report Segment by Region
North America
• US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East and Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/tyrosine-kinase-inhibitor-market